CORPORATE OVERVIEW

Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation

contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as

"may," "will," "should," "expect," "plan," "anticipate," "seek," "could," "intend," "target," "aim,"

"project," "designed to," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to

identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, our belief that Invivyd is poised to enter a

transformational period, and our preparations for potential commercial launch of VYD222 if our request for Emergency Use Authorization (EUA) is granted; the potential scope of an EUA for VYD222, if granted, including disease state and patient

population; our mission to rapidly deliver antibodies that protect vulnerable populations from viral threats; the future of the COVID- 19 landscape; our expectations regarding the size of target patient populations and the potential market

opportunity for our product candidates, as well as our market position; our beliefs regarding the clinical utility of anti-SARS-CoV-2 monoclonal antibodies (mAbs); the potential of the company's INVYMAB platform approach to rapidly,

serially generate new antibodies to address viral threats; the anticipated broad activity and prolonged utility of VYD222; the progress and timing of our ongoing research and clinical development activities, including with respect to VYD222; the

CANOPY clinical trial design, including our plans to use an immunobridging approach comparing data obtained in the CANOPY clinical trial to certain historical adintrevimab data; our expectation that historical adintrevimab data from the

company's EVADE clinical trial may accelerate VYD222 development; the potential of VYD222 for strong clinical protection from symptomatic COVID-19 based on early signals observed in the CANOPY clinical trial; the ability to have VYD222

commercially available in the U.S. rapidly, if EUA is granted; the potential of our pipeline of product candidates which, if authorized or approved, could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and

expanding into influenza and other high-need indications; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue

reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements,

including, without limitation: the timing and progress of our discovery, preclinical and clinical development activities; our ability to generate the clinical data needed from the CANOPY clinical trial to support a potential EUA for VYD222; our

interactions with the U.S. FDA regarding the EUA submission for VYD222; the outcome of the VYD222 EUA submission and the timing thereof; the development and regulatory pathways for authorization or approval of VYD222 or other product candidates;

unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of VYD222 or other product candidates based on neutralizing activity in preclinical studies; the risk that results of

preclinical studies or clinical trials may not be predictive of future results in connection with current or future clinical trials; our reliance on third parties with respect to virus assay creation and product candidate testing and with respect to

our clinical trials; variability of results in models used to predict activity against SARS-CoV-2 variants of concern; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory

authorization or approval process; whether our platform approach enables us to rapidly, serially generate new antibodies to address viral threats; whether VYD222 or any other product candidate is able to demonstrate and sustain neutralizing activity

against relevant, major or predominant SARS-CoV-2 variants, particularly in the face of viral evolution; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of VYD222 or any other product candidate following EUA

or approval, if granted; whether we are able to successfully submit an EUA for any other product candidate in the future, and the outcome and timing of any such EUA submission; our ability to manufacture sufficient commercial quantities of VYD222;

the complexities of manufacturing mAb therapies and our reliance on contract manufacturers to do so; our ability to establish a sales, marketing and distribution infrastructure to commercialize VYD222 or any other product candidates for which we may

obtain regulatory approval or EUA; whether we can obtain and maintain third-party coverage and adequate reimbursement for VYD222 or any other product candidate; whether our research and development efforts will identify and result in safe and

effective therapeutic options for infectious diseases other than COVID-19; our ability to continue as a going concern; and whether we have adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that

may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the

year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC), and in our other filings with the SEC, and in our future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in

this presentation are made as of this date, and we undertake no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. 2024 Invivyd, Inc. Invivyd, Invymab

and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. 2

INVIVYD IS POISED TO ENTER A TRANSFORMATIONAL PERIOD, WITH A NEAR-TERM

OPPORTUNITY TO DELIVER A MUCH NEEDED THERAPEUTIC In January 2024, Invivyd announced the submission of a request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the pre-exposure prevention of COVID-19 in immunocompromised

adults and adolescents VYD222 EUA submission is based on positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial and ongoing in vitro neutralization activity against major SARS- CoV-2 variants, including JN.1 Company

continues preparations for potential commercial launch of VYD222 if EUA is granted 3

INVIVYD IS ON A MISSION TO RAPIDLY DELIVER ANTIBODIES THAT PROTECT

VULNERABLE POPULATIONS FROM VIRAL THREATS, STARTING WITH COVID-19 Near-Term Opportunity >9M Zero EUA pathway provides the potential immunocompromised people authorized or approved opportunity to rapidly bring in the U.S. alone who may not

monoclonal antibodies VYD222, a mAb candidate, to adequately respond to (mAbs) in the U.S. to 1 COVID-19 vaccination prevent symptomatic immunocompromised adults and adolescents for the pre-exposure COVID-19 prevention of COVID-19 Reference: 1.

Estimated market opportunity based on Invivyd-sponsored market research and internal analysis 4

MANY IMMUNOCOMPROMISED PEOPLE HAVE AN IMPAIRED IMMUNE RESPONSE TO

COVID-19 VACCINES Immunocompromised people are less likely to have detectable SARS-CoV-2 antibodies following vaccination than immunocompetent people 1 Seroconversion rates (detectable Abs) in immunocompromised people vs. immunocompetent controls

after two COVID-19 vaccine doses [pre-Omicron] Immunocompetent Immunocompromised 98% 98% 98% 100% 90% 80% 74% 70% 62% 60% 50% 43% 40% 30% 20% 10% 0% Haematological Organ Transplant Immune-Mediated cancers (Weighted average of Inflammatory Disorders

24 studies) (Weighted average of (Weighted average 19 studies) of 17 studies) References: 1. Lee BMJ 2022; Abs, antibodies 5 Seroconversion rates (%)

DESPITE VACCINATION, IMMUNOCOMPROMISED PEOPLE REMAIN AT HIGHER RISK FOR

SEVERE COVID-19 OUTCOMES 1 The recent INFORM study, conducted during the Omicron period, found that in a sample of nearly 12 million people: Immunocompromised (IC) people represented only IC individuals accounted for IC individuals accounted for

3.9% of the study population 22% of COVID-19 hospitalizations 24% of COVID-19 deaths IC IC IC YET Immunocompetent Immunocompetent Immunocompetent Immunocompetent Even though >80% of the IC population had received 3 COVID-19 vaccines

References: 1. Evans Lancet Reg 2023 6

SIGNIFICANT MARKET OPPORTUNITY WITH >9M IMMUNOCOMPROMISED PEOPLE AT

INCREASED RISK FOR SEVERE COVID-19 IN THE U.S. Estimated U.S. total addressable market (TAM) for PrEP Of the estimated 485K High immunocompromised (IC) people at highest risk: 485K - 67K: stem cell transplants 2M - 86K: solid

organ transplants (e.g., RA, primary (liver/lung/kidney) immunodeficiency 3M diseases) - 332K: hematologic/lymphatic (e.g., non- cancers hematologic 4M cancer, IBD, MS) Care for these populations is often associated with specialized

centers (e.g., early-stage kidney disease, virally-suppressed HIV) Low High Risk of severe COVID-19 based on HCP surveys Reference: Illustrative graph and estimated market opportunity based on Invivyd-sponsored market research and internal analysis.

PrEP: Pre-exposure prophylaxis (prevention); RA: rheumatoid arthritis; IBD: inflammatory bowel disease; MS: multiple sclerosis; HIV: human immunodeficiency virus; HCP: Healthcare professional 7 Expected uptake of a COVID PrEP mAb based on HCP

IN ADDITION TO PREVENTION, MONOCLONAL ANTIBODIES ALSO HAVE COMPELLING

POTENTIAL IN THE TREATMENT OF COVID-19 PREVENTION TREATMENT Vaccines mAbs Antivirals Anti-SARS-CoV-2 mAbs are expected to provide: Rapid, passive immunity Limitations for the Limitations for the immunocompromised: Utility for

prevention or immunocompromised: outpatient treatment People with impaired Significant drug-drug Favorable tolerability without immune systems may not interactions can limit the significant drug-drug 2 generate protective levels utility of

some oral interactions of antibodies following antivirals as a treatment 1 vaccination option for this 3 population References: 1. Lee BMJ 2022; 2. McCreary JAMA Netw Open 2023; 3. Marzolini Clin Pharmacol Ther 2022 8

Our Platform & VYD222 2024 Invivyd, Inc. Invivyd and the

Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.

INVYMAB PLATFORM APPROACH IS DESIGNED FOR RAPID, SERIAL

GENERATION OF NEW ANTIBODIES TO ADDRESS VIRAL THREATS The company's proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody discovery and engineering VIRAL SURVEILLANCE

& ANTIBODY DISCOVERY ANTIBODY ENGINEERING PREDICTIVE MODELING Continuous monitoring of viral evolution Deep B-cell mining to isolate Industry-leading antibody engineering to and mapping of common mutational broadly neutralizing mAbs that target

rare viral improve potency, breadth, biophysical escape routes with the aim to predict epitopes that are not under strong immune pressure, properties, and developability of candidates potential future variants of concern increasing the probability

of sustained utility discovered through B-cell mining STREAM OF MAB CANDIDATES 10

VYD222: A CANDIDATE FOR THE PRE-EXPOSURE PREVENTION OF COVID-19 IN

IMMUNOCOMPROMISED ADULTS AND ADOLESCENTS Ph 2/3 clinical trial of ADG20 for COVID-19 prevention RBD Spike ACE2 Ph 2/3 clinical trial of ADG20 for COVID-19 treatment Broadly neutralizing, half-life extended Binds to the spike protein receptor

Engineered from adintrevimab mAb candidate in development for the binding domain (RBD) of SARS-CoV-2, (ADG20), a mAb candidate that Invivyd pre-exposure prevention of COVID-19 in interfering with the virus's ability to infect previously

studied in 2 clinical trials with immunocompromised adults and human cells clinical endpoints; data from the EVADE adolescents trial expected to accelerate VYD222 development Reference: Saxena SK VirusDis 2020 (SARS-CoV-2 figure) 11

VYD222 HAS DEMONSTRATED BROAD IN VITRO NEUTRALIZING ACTIVITY AGAINST

VARIOUS PRE-OMICRON AND OMICRON VARIANTS 1 VARIANT SUBLINEAGE VYD222 WT(D614G) WT(D614G) Delta B.1.617.2 BA.4.6 BF.7 XBB.1 XBB.1.5 XBB.1.16 Omicron XBB.1.5.10/EG.5 HK.3

BA.2.86 HV.1 JN.1 is currently the dominant 2 SARS-CoV-2 variant in the U.S. JN.1 References: 1. VYD222 data generated by CRO using a pseudovirus SARS-CoV-2 neutralizing Neutralizing activity in standardized in

vitro pseudovirus assays antibody assay; 2. https://covid.cdc.gov/covid-data-tracker/#variant-proportions (accessed Jan 5, 2024) 12

INVIVYD IS RAPIDLY ADVANCING VYD222 FOR THE PRE-EXPOSURE PREVENTION OF

COVID-19 IN IMMUNOCOMPROMISED ADULTS AND ADOLESCENTS Ph 1 to EUA submission in ~9 months Reported Dosed first Reported Dosed first positive initial participants in positive initial participant in Ph 1 trial Ph 1 data Ph 3 pivotal trial Ph 3 results

Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Initiated manufacturing Announced Completed Announced of potential commercial general alignment enrollment in submission of EUA inventory w/ FDA on pathway Ph 3 trial request to FDA to potential EUA

VYD222 EUA SUBMISSION IS BASED ON POSITIVE INITIAL RESULTS FROM THE

ONGOING PHASE 3 VYD222 CLINICAL TRIAL (CANOPY) VYD222 4500 mg IV (n 300) Initial CANOPY results reported COHORT A Open Label in December 2023: Immunocompromised // (N 300) Day 1 Month 3 Month 12 VYD222 produced high sVNA (Dosing)

(Redosing) (Last visit) titer levels against XBB.1.5 in Primary endpoints: Safety/tolerability immunocompromised participants Day 28 serum virus neutralizing antibody (sVNA) titers (calculated from the Overall favorable

safety and pharmacokinetic concentrations of tolerability profile of VYD222 VYD222 and the IC value for VYD222 50 against relevant SARS-CoV-2 variants) including no study drug-related SAEs; AEs attributed to VYD222 were Grade 1 or 2 (mild or VYD222

4500 mg IV (n 300) moderate) in severity COHORT B 2:1 Randomization At risk of SARS-CoV-2 // Potential early signal of strong exposure (N 450) Month 12 Day 1 Month 3 (Last visit) clinical protection from (Dosing) (Redosing)

Primary endpoints: symptomatic COVID-19 Safety/tolerability Placebo IV (n 150) Proportion of participants with RT-PCR-confirmed symptomatic COVID-19 through 6 months 14 Source: ClinicalTrials.gov Identifier: NCT06039449; IV,

intravenous; SAEs, serious adverse events; AEs, adverse events

IF AUTHORIZED, INVIVYD AIMS TO HAVE VYD222 COMMERCIALLY AVAILABLE IN

THE U.S. RAPIDLY THEREAFTER Commercial preparations are being led by a seasoned team with extensive experience successfully commercializing products within the infectious disease space Preparations completed or underway: Go-to-market planning (e.g.,

market research, market sizing/segmentation, brand strategy, field force sizing) Market access activities (e.g., payer/pricing research, distribution channels) Manufacturing initial commercial inventory Establishing necessary internal systems and

technology to support the transition to commercial stage Invivyd plans to concentrate initially on serving the highest risk IC populations through a highly focused field sales organization which can expand to reach additional IC adults and

adolescents over time, if VYD222 is authorized 15

VYD222 IS ONE OF MANY ANTIBODIES IN INVIVYD'S PIPELINE DISCOVERY/

PROGRAMS PLATFORM INDICATION(S) IND-ENABLING PHASE 1 PHASE 2 PHASE 3 STATUS PRECLINICAL SARS-COV-2 Reported positive initial Pre-exposure VYD222 mAb Ph 3 results and submitted prevention EUA request COVID Prevention or Engineering variant mAb

candidate #2 treatment matching COVID Prevention or Engineering variant mAb candidate #3 treatment matching COVID Prevention or Engineering variant mAb candidate #4 treatment matching Adintrevimab mAb Prevention Trials concluded; EUA filing

dependent on variant susceptibility Adintrevimab mAb Treatment OTHER VIRUSES mAb Influenza Prevention Early discovery combination Investigational therapies are not approved for use by regulatory authorities. The safety and efficacy of pipeline

candidates have not been established. 16

MANAGEMENT TEAM WITH EXPERTISE IN INFECTIOUS DISEASES AND TRACK RECORD

OF SUCCESS Peter C. Schmidt, M.D., MSc Stacy Price, M.S. William Duke, M.B.A Dave Hering, M.B.A. Chief Medical Officer Chief Technology & Manufacturing Officer Chief Financial Officer Chief Executive Officer & Director Jill Andersen, J.D.

Jeremy Gowler Robert Allen, Ph.D. Chief Legal Officer & Corporate Secretary Chief Operating & Commercial Officer Chief Scientific Officer 17